Boothbay Fund Management’s CRISPR Therapeutics CRSP Stock Holding History

Boothbay Fund Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,269	Closed	-$1.14M	–	1629
2023 Q4	$1.14M	Buy	18,269 +12,017	+192%	+$664K	0.03%	683
2023 Q3	$284K	Buy	+6,252	New	+$323K	0.01%	1270
2021 Q4	–	Sell	-3,019	Closed	-$338K	–	1910
2021 Q3	$338K	Sell	3,019 -10,615	-78%	-$1.33M	0.01%	1265
2021 Q2	$2.21M	Buy	13,634 +11,864	+670%	+$1.44M	0.07%	344
2021 Q1	$216K	Buy	+1,770	New	+$267K	0.01%	1333
2019 Q3	–	Sell	-22,905	Closed	-$1.09M	–	786
2019 Q2	$1.08M	Buy	+22,905	New	+$915K	0.1%	249

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boothbay Fund Management's CRSP Position: Q1 2024 in Review

Boothbay Fund Management sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 18,269 shares — an estimated $1.14M sold.

Boothbay Fund Management first reported a position in CRSP in Q2 2019 and held it in 6 quarters. The position peaked at $2.21M in Q2 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

Boothbay Fund Management reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
Boothbay Fund Management sold 18,269 CRISPR Therapeutics shares in Q1 2024, an estimated $1.14M.
Boothbay Fund Management first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 6 quarters.
Boothbay Fund Management's CRISPR Therapeutics position peaked at $2.21M in Q2 2021.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.